https://www.selleckchem.com/pr....oducts/wnt-agonist-1
Giant cell tumor of bone (GCT is a destructive lesion with a high potential for recurrence. RANK-ligand targeted therapy has provided promising, yet mixed results. Sclerostin (SOST) inhibition results in a net anabolic response and is currently used in the treatment of osteoporosis. The application to GCTB is unknown. We sought to determine if GCTB stained for SOST on immunohistochemistry and correlate its expression with predictor variables. All patients at a single institution undergoing surgery for GCTB between 1993 and 2008
Like
Comment
Share
